Lataa...
Generalization of the time-to-event continual reassessment method to bivariate outcomes
This article considers the problem of designing Phase I-II clinical trials with delayed toxicity and efficacy outcomes. The proposed design is motivated by a Phase I-II study evaluating all-trans retinoic acid (ATRA) in combination with a fixed dose of daratumumab in the treatment of relapsed or ref...
Tallennettuna:
| Julkaisussa: | J Biopharm Stat |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6823630/ https://ncbi.nlm.nih.gov/pubmed/31264936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10543406.2019.1634087 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|